Lv22
150 积分 2024-09-05 加入
Upadacitinib for Treatment of Coexisting Allergic Contact Dermatitis and Atopic Dermatitis: A Small Case Series
13小时前
求助中
Post-Marketing Safety Analysis of Upadacitinib in Atopic Dermatitis: An FDA Adverse Reporting System (FAERS) Review of Boxed Warning Related Adverse Events
13小时前
已完结
Evaluation of Upadacitinib efficacy in the treatment of Atopic Dermatitis of sensitive areas
13小时前
求助中
Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis
14小时前
已完结
The Transition of Blood Biomarkers During 96-Week Treatment with Upadacitinib for Atopic Dermatitis: A Real-World Analysis Stratified by Age
14小时前
求助中
Efficacy and safety of oral JAK1 inhibitor upadacitinib monotherapy for papulopustular rosacea: A real-world study
14小时前
已完结
Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab
14小时前
已完结
Deciding which patients with atopic dermatitis to prioritize for biologics and Janus kinase inhibitors
14小时前
求助中
Patients With Atopic Dermatitis Treated With Upadacitinib: Factors Related to Achieving Minimal Disease Activity
14小时前
求助中
Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched Study
1天前
求助中
皖公网安备34019202002308
